Background: The rapid spread of SARS-CoV-2 has caused havoc and panic among individuals, which has further worsened due to the unavailability of a proven drug(s) regime.

Objective: The current work involves drug repurposing from the pool of USFDA approved drugs involving in silico virtual screening technique against COVID-19.

Materials and Methods: Methodology involves virtual screening of 8548 FDA approved drugs against target protein endoribonuclease NendoU (Nsp15) (PDB ID: 6VWW).

Result: Virtual screening-based analysis enabled us to identify four drugs, Eprosartan, Inarigivir soproxil, Foretinib, and DB01813 that could plausibly target Nsp15 against COVID-19 disease.

Conclusion: The work offers the scope to corroborate the findings via in vitro and in vivo techniques to identify the potential of selected leads against COVID-19. The outcome may also help in tracing their molecular mechanism(s) in addition to their development at the clinical level in the future.

背景：SARS-CoV-2 的快速传播在个人中造成了严重破坏和恐慌，由于没有经过验证的药物方案，这种情况进一​​步恶化。

目标：目前的工作涉及从 USFDA 批准的药物池中重新利用药物，这些药物涉及针对 COVID-19 的计算机虚拟筛选技术。

材料和方法：方法学涉及针对靶蛋白内切核糖核酸酶 NendoU（Nsp15）（PDB ID：6VWW）对 8548 种 FDA 批准的药物进行虚拟筛选。

结果：基于虚拟筛选的分析使我们能够确定四种药物，依普罗沙坦、Inarigivir soproxil、Foretinib 和 DB01813，它们可以合理地针对 Nsp15 对抗 COVID-19 疾病。

结论：这项工作提供了通过体外和体内技术证实这些发现的范围，以确定选定的线索对抗 COVID-19 的潜力。除了未来在临床水平上的发展外，该结果还可能有助于追踪其分子机制。